Physician profile
Leonard W Ostrowski
NPI 1881691947
$6,799.86
in general payments reported to CMS, 2019-2025
46 companies · $803 in 2025
The $803 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,757 · 2020: $1,045 · 2021: $847 · 2022: $901 · 2023: $708 · 2024: $739 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,250.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,225.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,103.09 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $561.56 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $512.26 | 2019-2020 | |
| Abbvie INC. | $479.16 | 2019-2025 | |
| Pfizer INC. | $464.79 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $425.19 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.82 | 2019-2024 | Stiolto Respimat, Spiriva Respimat, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $160.92 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $157.84 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.20 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $130.63 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $127.87 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $103.47 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $68.44 | 2024-2025 | Voquezna |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Ostrowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.